Contribution of pressure and flow changes to resistance reduction after pulmonary arterial hypertension treatment: a meta-analysis of 3898 patients.

Ioannis T FarmakisAmalia BaroutidouVasiliki PatsiouAlexandra ArvanitakiIoannis DoundoulakisLukas HobohmStefanos ZafeiropoulosStavros V Konstantinides Michele D'AltoRoberto BadagliaccaGeorge Giannakoulas

Published in: ERJ open research (2024)

Combination therapies, especially with the inclusion of parenteral prostanoids, lead to remarkable haemodynamic improvement in treatment-naïve PAH patients and may unmask the contribution of mPAP reduction to the overall PVR reduction in addition to the increase in CO.

Keyphrases

pulmonary arterial hypertension
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
pulmonary hypertension
patient reported outcomes
replacement therapy